Biological Intellectual Property Protection Act of 2025
Summary
The Biological Intellectual Property Protection Act of 2025 (HR6624) has been ordered to be reported out of the House Foreign Affairs Committee, indicating progress towards a floor vote. This bill aims to restrict the export of U.S. intellectual property and sensitive information related to synthetic biology to foreign entities of concern, specifically citing the People's Republic of China.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6624 restricts export of U.S. synthetic biology IP to foreign entities of concern, primarily China.
- 2.The bill has advanced out of the House Foreign Affairs Committee and awaits a full House vote.
- 3.No direct funding is authorized or appropriated by this bill; its impact is regulatory.
- 4.A companion bill (S3452) exists in the Senate, suggesting broader legislative support.
Market Implications
The Biological Intellectual Property Protection Act of 2025 (HR6624) introduces new regulatory hurdles for companies in the synthetic biology sector involved in international trade, particularly with China. While no specific tickers are named, companies engaged in synthetic biology research, development, and manufacturing that have significant intellectual property or export operations will need to assess their compliance strategies. The bill's advancement indicates a continued focus on national security and intellectual property protection within the U.S. legislative agenda, potentially influencing long-term investment and operational decisions in the Healthcare and Technology sectors related to biotechnology.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Preventing Research Ownership Transfer to External Competitive Threats (PROTECT) Act of 2026
To expand the sharing of information with respect to suspected violations of intellectual property rights in trade.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.